HOME >> BIOLOGY >> NEWS
Delivering the fruits of biotechnology to the developing world: Institute for Global Health sponsors global health forum, February 18-21

Leaders from governments, biotechnology companies, and multi-lateral agencies from around the world will gather in Carmel Valley, CA, February 18-21 to study how best to promote development of drugs and vaccines for the world's poorest countries. This Global Health Forum: "Creating Global Markets for Orphan Drugs & Vaccines: A Challenge for Public/Private Partnership," will be sponsored by the Institute for Global Health, of the University of California, San Francisco, and UC Berkeley.

Although the forum is closed to the press and the public, its participants will publish a set of conclusions and recommendations for action. They will discuss these recommendations at a press briefing in San Francisco, Tuesday, February 22.

As the biotechnology and vaccine industries have blossomed in recent decades, they have focused predominantly on diseases affecting the world's richest countries. Diseases that plague poor countries, such as malaria and sleeping sickness, have been largely ignored, said Dr. Richard Feachem, PhD, DSc(Med), founding director of the Institute for Global Health, and a professor of international health at UCSF and UC Berkeley.

"Modern biomedical science and biotechnology are beginning to deliver fantastically powerful new drugs and new vaccines. We must find ways to bring the fruits of medical science to all people in the world who could benefit from them. If we fail, the consequences will be catastrophic," he said.

Without a more concerted effort, the epidemics developing countries are now facing will reach catastrophic proportions, Feachem said. "In a few years, malaria will be untreatable, and HIV will have caused devastation in Asia as it has already in Africa," he said. Malaria parasites are quickly becoming resistant and there are no new drugs in the development pipeline, and HIV vaccines that low income countries can afford and use are still years away, he

Several public/private partnerships targeting individual diseas
'"/>

Contact: Kevin Boyd
kboyd@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
6-Feb-2000


Page: 1 2 3

Related biology news :

1. More people are getting sick from eating fresh fruits
2. Middle-aged women who consume many fruits and vegetables are at much lower risk of cardiovascular disease
3. Rensselaer marks the opening of the center for biotechnology and interdisciplinary studies
4. UK biotechnology business plan competition now open to students in the US and Canada
5. Plants for the future: A European vision for plant biotechnology towards 2025
6. University of Pittsburgh Medical Center acquires biotechnology firm Rheogene Inc.
7. Poll: NY residents split on biotechnology in food and agriculture
8. First company founded on UCF biotechnology formed
9. NASA biotechnology activities enhancing quality of life
10. Genetic engineering accelerates the impact of biotechnology on chemical production
11. Symposium to focus on ethical issues in biotechnology

Post Your Comments:
(Date:3/20/2015)... Conn. , March 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... smart wallet is one of the products featured in ... March 20th at 11:00 PM EST on the DIY ... to Las Vegas , site of ...
(Date:3/17/2015)... 2015 Emotient, the leader in facial ... general availability of Emotient Analytics , the ... of facial expressions. The system analyzes videos of ... and services. It delivers audience response metrics - ... as derived from facial evidence of emotional states. ...
(Date:3/12/2015)... BERLIN , March 12, 2015 ... IAM, a standardized identity and access management (IAM) ... reliable implementation schedule. With Beta System,s new IAM ... and best practices gleaned from multiple IAM implementations ... includes the software as well as any necessary ...
Breaking Biology News(10 mins):NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2
(Date:4/2/2015)... 02, 2015 InGaAs PIN photo diodes ... sensitivity and high-speed response. Marktech introduces the newest series ... can with active areas of 0.1mm, 0.3mm and 0.8mm. ... and high speed fiber modules. , Standard spectral range ... These parts offer considerable speed improvements over the current ...
(Date:4/1/2015)... , April 1, 2015  Adaptive Biotechnologies ... The Lancet Oncology showing that ... company,s next-generation sequencing-based minimal residual disease (MRD) detection ... MRD test) accurately identifies patients with diffuse large ... relapse after initial treatment, usually several months before ...
(Date:4/1/2015)... -- Emerson Ecologics is excited to announce its first ... . The conference will provide integrative healthcare practitioners with ... fulfilling practice. Scheduled for November 13-15, ... the conference will be a one-of-a-kind, "get it done" ... and leave with an action plan in hand. Highlights ...
(Date:4/1/2015)... , April 1, 2015  ValGenesis Inc., the market ... today that it has completed its Service Organization Controls ... Engagements (AICPA, Professional Standards) for the period of January ... 2014.  ... The SOC 2 examination ...
Breaking Biology Technology:Marktech Optoelectronics Announces High Speed InGaAs PIN Diode 1.7µm 2Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 2Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 3Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 4Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 5Emerson Ecologics Announces First Annual Conference for Integrative Healthcare Practitioners 2Emerson Ecologics Announces First Annual Conference for Integrative Healthcare Practitioners 3ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 2ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 3
Cached News: